NOVARTIS, ONO TO MARKET ALZHEIMER'S DRUG IN JAPAN

A A

Novartis (NOVN.VX: Quote, Profile, Research) and Japan's Ono Pharmaceuticals Co. (4528.OS: Quote, Profile, Research) said on Monday they have agreed to jointly develop and market the Swiss drugmaker's alzheimer's drug ENA713D in Japan. The drug, which is now in phase II clinical trials in Japan, is sold as Exelon in more than 70 countries abroad. The terms of the agreement were not disclosed.

Reuters (http://today.reuters.com/business/newsArticle.aspx?type=health&storyID=nTKV002400)